ECONOMIC ANALYSIS OF ETANERCEPT AS CONTINUOUS OR PAUSED THERAPY IN MODERATE TO SEVERE PSORIASIS FROM A PUBLIC PERSPECTIVE IN VENEZUELA

被引：0
|
作者：
Fernandes, R. A. [1 ]
Takemoto, M. L. S. [1 ]
Amaral, L. M. [1 ]
Cruz, R. B. [1 ]
Mould, J. F. [2 ]
Rodriguez, J. C. [3 ]
机构：
[1] ANOVA Knowledge Translat, Rio De Janeiro, RJ, Brazil
[2] Pfizer Inc, New York, NY USA
[3] Pfizer Inc, Caracas, Venezuela
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A251 / A252
页数：2
相关论文
共 50 条
  • [41] Cost per responder of apremilast and etanercept in patients with moderate to severe plaque psoriasis using results from LIBERATE
    Tencer, Tom
    Clancy, Zoe
    Zhang, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB242 - AB242
  • [42] Economic Evaluation of Selected Interleukin Inhibitors Versus Methotrexate for Moderate-to-Severe Plaque Psoriasis From the Philippine Payer Perspective
    Kimwell, Miharu Jay M.
    de Guzman, Denese C.
    Onda, Arwin Jerome M.
    Dofitas, Belen L.
    Frez, Lorna F.
    Mendoza, Clarisse G.
    Rivera IV, Francisco D.
    Almirol, Bernadette Joy Q.
    Malaluan, Mark Jayson Q.
    Guce, Kristel
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 34 : 100 - 107
  • [43] ETANERCEPT IN EARLY RHEUMATOID ARTHRITIS: ECONOMIC EVALUATION FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
    Takemoto, M.
    Fernandes, R. A.
    Fujii, R. K.
    Mould, J.
    Tang, B.
    VALUE IN HEALTH, 2012, 15 (07) : A512 - A513
  • [44] Cost effectiveness of biologics for moderate to severe psoriasis from the perspective of the Swiss healthcare system
    Greiner, R.
    Braathen, L. R.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 : 54 - 54
  • [45] Efficacy and safety of Etanercept for the treatment of moderate-to-severe psoriasis when used with adjunctive topical therapy as needed: The PRISTINE trial
    Strohal, R.
    Puig, L.
    Robertson, D.
    Estojak, J.
    Pedersen, R.
    Melin, J.
    Freundlich, B.
    Molta, C. T.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2011, 52 : 36 - 36
  • [46] Efficacy and safety of etanercept for the treatment of moderate-to-severe psoriasis when used with adjunctive topical therapy as needed: the PRISTINE Trial
    Strohal, Robert
    Puig, Lluis
    Robertson, Deborah
    Estojak, Joanne
    Pedersen, Ronald
    Melin, Jeffrey
    Freundlich, Bruce
    Molta, Charles
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S68 - S68
  • [47] A 12-week phase 3 study of efficacy and safety of etanercept therapy in children and adolescents with moderate to severe plaque psoriasis
    Paller, Amy
    Siegfried, Elaine
    Langley, Richard
    Gottlieb, Alice
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB195 - AB195
  • [48] COST PER RESPONDER ANALYSIS OF USTEKINUMAB VERSUS SECUKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
    Araujo, R. L.
    Scaccabarozzi, L.
    Asano, E.
    VALUE IN HEALTH, 2017, 20 (05) : A220 - A220
  • [49] A retrospective analysis of combination methotrexate-cyclosporine therapy in moderate-severe psoriasis
    Mohanan, Saritha
    Ramassamy, Sivaranjini
    Chandrashekar, Laxmisha
    Thappa, Devinder Mohan
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2014, 25 (01) : 50 - 53
  • [50] Ustekinumab treatment in patients with moderate to severe psoriasis who are nonresponders to etanercept: Results from a phase III clinical trial
    Griffiths, Christopher E. M.
    Menter, Alan
    Strober, Bruce E.
    Yeilding, Newman
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB137 - AB137
12345